Standard Nivolumab Dosing
Nivolumab (Opdivo) uses body weight-based dosing of 240 mg every 2 weeks or 480 mg every 4 weeks for most adults with solid tumors, or 3 mg/kg every 2 weeks in combination regimens. Fixed dosing replaced earlier mg/kg schedules for simplicity.[1]
Adjustments for Mild Kidney Impairment
No dose adjustment needed for mild renal impairment (creatinine clearance 30-80 mL/min). Pharmacokinetics remain similar, with clearance unaffected by reduced kidney function at this level.[2][3]
Handling Moderate to Severe Kidney Impairment
No specific dose changes required for moderate (CrCl 15-29 mL/min) or severe (CrCl <15 mL/min) impairment, including end-stage renal disease or dialysis patients. Studies show nivolumab exposure, efficacy, and safety profiles are comparable across renal function levels, as the drug is primarily cleared hepatically via metabolism, not kidneys.[2][4]
Why Kidney Function Has Minimal Impact
Nivolumab, a monoclonal antibody, undergoes target-mediated disposition and proteolytic catabolism in the reticuloendothelial system, bypassing renal excretion. Population pharmacokinetic analyses confirm no clinically significant changes in AUC or half-life with declining CrCl.[3][5]
Monitoring and Real-World Considerations
Assess kidney function via Cockcroft-Gault or MDRD before starting, but routine adjustments aren't needed. Immune-related adverse events (e.g., nephritis) can worsen renal function—monitor creatinine and urine protein. In trials like CheckMate, renal impairment didn't alter progression-free survival or overall response rates.4
Special Cases: Dialysis and Pediatrics
Safe in dialysis patients with standard dosing; administer post-dialysis if scheduled. Limited pediatric data follows adult guidelines without renal adjustments.[2]
Sources
[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf (Opdivo Label)
[2]: https://www.opdivo.com/
[3]: https://pubmed.ncbi.nlm.nih.gov/25965237/ (PK study in renal impairment)
[4]: https://pubmed.ncbi.nlm.nih.gov/28855168/ (CheckMate renal subgroup)
[5]: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2190 (PopPK analysis)